Using small molecules to degrade dengue virus proteins as a treatment approach
Small molecule-induced degradation of dengue proteins as an antiviral strategy
This study is exploring a new way to fight the dengue virus by using special small molecules that help get rid of the virus's harmful proteins in infected cells, aiming to create a better treatment option for people dealing with dengue.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-10886701 on NIH RePORTER |
What this research studies
This research investigates a novel antiviral strategy that employs small molecules to induce the degradation of proteins associated with the dengue virus. By utilizing innovative techniques involving chimeric molecules that target specific proteins for destruction, the study aims to overcome the challenges posed by the genetic diversity of the dengue virus. This approach seeks to provide a more effective treatment option by removing viral proteins from infected cells, potentially leading to better patient outcomes. The research is focused on developing a method that does not rely on constant engagement with the target, allowing for effective treatment even with modestly binding compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been diagnosed with dengue virus infection and are seeking new treatment options.
Not a fit: Patients who are not infected with the dengue virus or those who have other unrelated viral infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new antiviral treatment for dengue virus infections, improving recovery and reducing disease severity for patients.
How similar studies have performed: Other research has shown promise in using similar small molecule-induced degradation strategies for antiviral treatments, indicating potential for success in this approach.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Yang, Priscilla Li-Ning — Stanford University
- Study coordinator: Yang, Priscilla Li-Ning
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.